AKT1 and breast carcinoma: Rabindran et al. [63] examined the effects of neratinib using human HER2-positive breast cancer cell lines, where it was found neratinib treatment down-regulated MAPK, Akt, and RB phosphorylation, down-regulated cyclin D1 expression, and up-regulated the cell cycle inhibitor p27 in a dose-dependent manner.